The ABCC3 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Huh-7 human hepatocellular carcinoma cells, featuring targeted disruption of the ABCC3 gene. This loss-of-function model is intended for researchers studying the roles of ABCC3 in drug transport, detoxification, and hepatocarcinogenesis, with polyclonality ensuring a heterogeneous editing landscape.
Huh-7 cells are epithelial cells originally isolated from a liver tumor of a 57-year-old Japanese male. They serve as a standard model in hepatic tumorigenesis, drug metabolism, and hepatitis C virus replication due to their robust growth and well-characterized hepatic properties.
ABCC3 encodes the multidrug resistance-associated protein 3 (MRP3), a basolateral ATP-dependent transporter that mediates the efflux of glucuronide conjugates, glutathione conjugates, and bile acids into the blood, constituting a critical step in phase III detoxification. Its expression is transcriptionally regulated by the farnesoid X receptor (FXR) in bile acid homeostasis and by NRF2 under oxidative stress, linking ABCC3 to both metabolic and cytoprotective pathways. At the membrane, ABCC3 interacts with NHERF1 and ERM proteins (ezrin, radixin, moesin), which anchor it to the actin cytoskeleton and support polarized localization. Through its export activity, ABCC3 reduces intracellular drug levels and promotes chemoresistance in liver cancer cells.
In the Huh-7 hepatocellular carcinoma background, ABCC3 knockout ablates a major efflux pump, potentially enhancing sensitivity to chemotherapeutics and underscoring its role in multidrug resistance. This model also allows dissection of bile acid transport and glucuronidation pathways, contributing to understanding of cholestatic liver diseases. Furthermore, impaired glutathione conjugate efflux may elevate oxidative stress, providing a tool to study NRF2-mediated redox responses in hepatic malignancy.
Applications include intracellular drug accumulation analysis by flow cytometry, fluorescent substrate efflux assays, and chemotherapy cytotoxicity tests to assess chemosensitization. Bile acid transport can be measured using radiolabeled or fluorescent bile acids. Knockout validation is performed via western blotting and RT-qPCR, while co-immunoprecipitation of ABCC3 with NHERF1 or ERM proteins and RNA-seq transcriptomics enable pathway analysis. This model is thus valuable for studies in hepatocellular carcinoma multidrug resistance, drug metabolism, and liver biology. For inquiries, contact Ascent Research.
